| Literature DB >> 23985956 |
Muhammad Said1, Amin Badshah, Naseer Ali Shah, Hizbullah Khan, Ghulam Murtaza, Boris Vabre, Davit Zargarian, Muhammad Rashid Khan.
Abstract
A series of N-pivaloyl-N'-(alkyl/aryl)-N''-pyridylguanidine of general formula C₄H₉CONHC(NR¹R²)NPy have been synthesized and characterized using elemental analysis, FT-IR, multinuclear NMR spectroscopy, and in the case of compounds 7 and 11, by single crystal X-ray diffraction (XRD). The synthesized guanidines were tested for antitumor activities against potato tumor, and showed excellent inhibition against Agrobacterium tumefaciens (AT10)-induced tumor. The antioxidant and antimicrobial activities of these new compounds against various bacterial and fungal strains were also investigated.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23985956 PMCID: PMC6269704 DOI: 10.3390/molecules180910378
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Synthesis of substituted pyridylguanidines 1–12.
Characteristic pyridylguanidine resonances by NMR spectroscopy.
| Compound | R1 | R2 | 1H | 13C | |||
|---|---|---|---|---|---|---|---|
| NH | NH | CN3 | C=O | ||||
|
| Phenyl | H | 11.39 | 14.52 | 161.6 | 180.6 | |
|
| 2-chlorophenyl | H | 11.91 | 14.49 | 161.2 | 180.2 | |
|
| 3-chlorophenyl | H | 11.32 | 14.46 | 161.3 | 180.9 | |
|
| 4-chlorophenyl | H | 11.26 | 14.48 | 161.3 | 180.7 | |
|
| 2-methoxyphenyl | H | 11.93 | 14.54 | 161.8 | 179.9 | |
|
| 4-tolyl | H | 11.36 | 14.53 | 161.8 | 180.6 | |
|
| 2-fluorophenyl | H | 11.79 | 14.47 | 161.3 | 180.5 | |
|
| H | 9.02 | 14.59 | 162.7 | 180.3 | ||
|
| H | 8.99 | 14.57 | 162.7 | 180.4 | ||
|
| H | 8.98 | 14.56 | 162.7 | 180.4 | ||
|
| 2-pyridyl | H | 12.08 | 14.36 | 161.3 | 180.0 | |
|
| 12.27 | ---- | 161.8 | 176.7 | |||
Crystal data and structure refinement parameters for compounds (7 and 11).
| Crystal parameters | 7 | 11 | |
|---|---|---|---|
| Empirical formula | C17H19N4OF | C16H19N5O | |
| Formula weight | 314.36 | 297.35 | |
| Temperature (K) | 296 | 200 | |
| Wavelength (Å) | 1.54178 | 1.54178 | |
| Crystal system | Monoclinic | Monoclinic | |
| Space group | P2(1)/n | P2(1)/n | |
| Unit cell dimensions | a (Å) | 10.7110(2) | 6.00430(10) |
| b(Å) | 9.9954(2) | 16.9550(2) | |
| c(Å) | 15.2679(4) | 15.2900(2) | |
| α(°) | 90 | 90 | |
| β(°) | 91.0430(10) | 92.4800(10) | |
| γ(°) | 90 | 90 | |
| V (Å3), Z | 1634.32(6),4 | 1555.11(4),4 | |
| Density (calcd) (g/cm3) | 1.278 | 1.270 | |
| Crystal size(mm3) | 0.10 × 0.08 × 0.08 | 0.14 × 0.12 × 0.10 | |
| Index ranges | −13 <= h <= 12 | −7 <= h <= 7 | |
| F(000) | 664 | 632 | |
| Total reflections | 21339 | 20265 | |
| Independent reflections | 3214 [Rint= 0.045] | 3032[Rint= 0.036] | |
| R indices (all data) | R1 = 0.0516 | R1 = 0.0464, | |
| Final R indices [I > 2σ(I)] | R1 = 0.0445, | R1 = 0.0402, | |
| Goodness-of-fit | 1.048 | 1.042 | |
| Theta range for data collection (°) | 5.00 to 72.64 | 3.89 to 72.53 | |
Selected bond lengths, bond angles and torsion angles for compounds 7 and 11.
| Compound | Bond lengths (Å) | Bond angles (°) | Torsion angles (°) | |
|---|---|---|---|---|
|
| C5-O1 1.2306(17) | C6-N1 1.4034(18) | N1-C6-N2 114.25(12) | O1-C5-N1-C6 1.0(2) |
| C6-N2 1.3613(17) | C6-N3 1.2929(18) | N1-C6-N3 123.83(12) | C5-N1-C6-N2 4.8(2) | |
| C5-N1 1.3644(18) | C7-N3 1.3985(17) | N2-C6-N3 121.92(13) | C5-N1-C6-N3 -175.45(14) | |
| C12-N2 1.4027(17) | C2-C5 1.526(2) | C5-N1-C6 128.79(12) | C6-N3-C7-N4 -5.5(2) | |
|
| C5-O1 1.2263(15) | C5-N1 1.3653(15) | N1-C6-N2 123.91(11) | O1-C5-N1-C6 0.2(2) |
| C6-N1 1.4017(15) | C6-N2 1.2918(15) | N1-C6-N3 114.67(10) | C5-N1-C6-N2 175.27(12) | |
| C6-N3 1.3623(15) | C7-N3 1.4003(15) | N2-C6-N3 121.42(11) | C5-N1-C6-N3 -5.09(18) | |
| C12-N2 1.3925(15) | C2-C5 1.5309(16) | C5-N1-C6 129.02(10) | C6-N3-C7-N4 177.02(12) | |
Figure 1ORTEP diagram for N-pivaloyl-N′-(2.fluorophenyl)-N″-pyridylguanidine (7). Thermal ellipsoids are shown at the 50% probability level. Hydrogen atoms are omitted for clarity.
Figure 2ORTEP diagram of N-pivaloyl-N′,N″-dipyridylguanidine (11). Thermal ellipsoids are shown at the 50% probability level. Hydrogen atoms are omitted for clarity.
Antitumor activity of synthesized guanidines.
| Compound | Average number of tumors per disc | % Inhibition of tumors |
|---|---|---|
|
| 2.0 | 73 |
|
| 1.5 | 80 |
|
| 2.0 | 73 |
|
| 3.0 | 60 |
|
| 2.0 | 73 |
|
| 1.5 | 80 |
|
| 2.0 | 73 |
|
| 3.0 | 60 |
|
| 2.0 | 73 |
|
| 2.0 | 73 |
|
| 3.0 | 60 |
|
| 1.5 | 73 |
|
| 7.5 | --- |
|
| 00 | 100 |
a Potato disc antitumor assay, concentration: 500 µg/mL in DMSO; b More than 20% tumor inhibition is significant; c Data represents mean value of 12 replicates.
Figure 3Percent scavenging of DPPH by compounds 1–12 at different concentrations (1000, 500, 250, 125, 62.5, 28 and 14 µg/mL) after 1, 24, 48 and 72 h. DPPH without sample was used as control.
In vitro antifungal activity of synthesized guanidines and standard drug.
| Compound | Mean Values of Percent Growth Inhibition | ||||
|---|---|---|---|---|---|
|
|
|
|
|
| |
|
| 10 ± 1.5 | 12.5 ± 2.0 | 20 ± 1.0 | --- | 47.5 ± 1.5 |
|
| --- | 72.5 ± 1.5 | 62.5 ± 2.5 | --- | 5 ± 0 |
|
| --- | 2.5 ± 1.5 | 20 ± 2.0 | --- | --- |
|
| --- | 79 ± 1.0 | 32.5 ± 1.5 | 25 ± 1.0 | --- |
|
| --- | 66.5 ± 1.5 | 65.3 ± 1.7 | --- | 42.5 ± 2.4 |
|
| --- | 72.5 ± 0.5 | 62.5 ± 0.5 | 5 ± 0.5 | 55 ± 1.0 |
|
| --- | 70 ± 2.0 | --- | 50 ± 1.0 | 5 ± 1.0 |
|
| 64.5 ± 1.5 | 42.5 ± 2.5 | 62.5 ± 1.5 | 40 ± 2 | 20 ± 0.5 |
|
| --- | 32.5 ± 0.5 | 40 ± 2 | 12.5 ± 0.5 | 12.5 ± 0.5 |
|
| --- | 27.5 ± 0.5 | 47.5 ± 1.5 | --- | 20 ± 1 |
|
| --- | --- | 25 ± 1.0 | --- | 30 ± 2 |
|
| --- | --- | 39.5 ± 1.5 | --- | 10 ± 0 |
|
| 100 | 100 | 100 | 100 | 100 |
|
| --- | --- | --- | --- | --- |
(a) --- Shows no activity; (b) In vitro agar tube dilution method; (c) concentration: 12 mg/mL of DMSO.
In vitro antibacterial activity (mean zone of inhibition) of synthesized guanidines and standard drugs.
| Compound | Mean zone of inhibition (mm) | |||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
|
| --- | --- | --- | --- | --- | --- |
|
| 15 ± 0.5 | 12 ± 0.8 | --- | --- | 15 ± 1.0 | 16 ± 0.6 |
|
| --- | --- | --- | --- | --- | --- |
|
| --- | --- | --- | --- | --- | --- |
|
| --- | --- | --- | --- | --- | --- |
|
| --- | --- | --- | --- | 18 ± 1.2 | --- |
|
| --- | --- | --- | --- | --- | --- |
|
| 15 ± 1.5 | 15 ± 0.5 | --- | --- | --- | 13 ± 1.5 |
|
| 14 ± 0.6 | 13 ± 1.2 | --- | 12 ± 0.2 | 12 ± 0.4 | --- |
|
| 15 ± 0.5 | 15 ± 0.7 | 13 ± 0.4 | 14 ± 0.8 | 17 ± 1.5 | 15 ± 0.7 |
|
| --- | --- | --- | --- | --- | --- |
|
| 12 ± 0.8 | 12 ± 0.6 | 12 ± 0.4 | --- | 16 ± 0.8 | --- |
|
| 25 ± 1.0 | 22 ± 0.6 | 22 ± 0.5 | 23 ± 1.0 | 25 ± 1.0 | 20 ± 0.5 |
|
| 30 ± 1.5 | 25 ± 1 | 30 ± 2.0 | 25 ± 1.0 | 26 ± 2.0 | 25 ± 1.0 |
Effective Minimum Inhibition Concentration (MIC) of synthesized guanidines against different bacterial strains.
| Compound | Minimum inhibitory concentration (MIC) mg/mL DMSO | |||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
|
| --- | --- | --- | --- | --- | --- |
|
| 0.0312 | 0.0078 | --- | --- | 0.0019 | 0.25 |
|
| --- | --- | --- | --- | --- | --- |
|
| --- | --- | --- | --- | --- | --- |
|
| --- | --- | --- | --- | --- | --- |
|
| --- | --- | --- | --- | 0.25 | --- |
|
| --- | --- | --- | --- | --- | --- |
|
| 1 | 1 | --- | --- | --- | 1 |
|
| 0.25 | 0.0156 | --- | 0.5 | 1 | --- |
|
| 0.5 | 0.25 | 1 | 1 | 0.5 | 0.5 |
|
| --- | --- | --- | --- | --- | --- |
|
| 0.5 | 0.125 | 0.0019 | --- | 0.0312 | --- |
(a) --- MIC not determined which is more than 1mg/mL; (b) agar well-diffusion method, 24 h incubation.